2019 年冠状病毒病 (COVID-19) 大流行是过去 3 年来对人类的最大威胁。它已造成全世界超过690万人失去宝贵生命。阻止屠杀的唯一方法是大规模接种疫苗或大规模免疫接种。患有自身免疫性风湿性疾病（AIRD）并接受免疫抑制剂治疗的患者是疫苗接种的优先候选者。然而，有关 COVID-19 疫苗对这组患者的疗效的数据非常少。因此，本研究计划研究 Covishield 对参加卢迪亚纳 DMCH 风湿病 OPD 的 AIRD 患者的免疫原性。这是一项前瞻性队列研究，由 Dayanand 医学院生物化学系和临床免疫学和风湿病学系计划和医院，卢迪亚纳。本研究包括 50 名参加 DMCH 风湿病 OPD 的 AIRD 患者以及 52 名年龄和性别匹配且已接受两剂 Covishield 疫苗的健康对照者。患有任何其他免疫抑制疾病（例如不受控制的糖尿病、肝炎、恶性肿瘤或艾滋病毒）的患者被排除在外。之前患有实验室确诊的 COVID-19 感染（通过 RT-PCR）的患者也被排除在外。在接种第二剂 Covishield 疫苗后第 28 天，在采取所有无菌预防措施后，从患者和对照中采集血液样本，并使用 Elecsys Anti- 测量严重急性呼吸综合征冠状病毒 2 尖峰 (S) 蛋白受体结合域的总抗体。罗氏公司的SARS-CoV-2 S试剂盒。观察到病例和对照之间的抗体滴度没有显着差异（6213±4418 vs. 8331±7979，P = 0.1022）。还观察到，未使用泼尼松龙的病例和接受泼尼松龙治疗的病例的抗体滴度没有统计学上的显着差异（P = 0.7058）。在甲氨蝶呤方面也发现了类似的观察结果（P = 0.457）。与对照相比，抗体滴度没有显着差异（泼尼松龙，P = 0.169，甲氨蝶呤，P = 0.078）。我们发现，与健康对照相比，只有接受霉酚酸酯治疗的患者抗体滴度出现统计学显着下降（P = 0.03）。我们的研究显示，患有不同 AIRD 的患者之间的抗体滴度没有统计学上的显着差异。我们的研究补充了这样一个事实：印度的 AIRD 患者可以接受 Covishield 作为针对 COVID-19 的主要疫苗，而无需担心免疫原性降低或不良反应增加。版权：© 2024 家庭医学和初级保健杂志。

The Coronavirus disease 2019 (COVID-19) pandemic has been the biggest threat to humankind during the last 3 years. It has caused the loss of more than 6.9 million precious lives across the world. The only method by which the massacre could be stopped was by mass vaccination or mass immunization. The patients suffering from autoimmune rheumatic disorders (AIRDs) and treated with immunosuppressants were the high-priority candidates for vaccination. However, the data regarding the efficacy of COVID-19 vaccines in this group of patients are very less. Hence, this study was planned to study the immunogenicity of Covishield in patients with AIRDs attending the rheumatology OPD at DMCH, Ludhiana.It was a prospective cohort study and was planned by the Department of Biochemistry and Department of Clinical Immunology and Rheumatology at Dayanand Medical College and Hospital, Ludhiana. Fifty patients with AIRDs attending the DMCH rheumatology OPD and 52 age and sex-matched healthy controls who had received two doses of Covishield vaccine were included in this study. Patients having any other immunosuppressive conditions like uncontrolled diabetes, hepatitis, malignancy or HIV were excluded. Patients who had suffered from previous laboratory-confirmed COVID-19 infection (by RT-PCR) were also excluded. Blood samples were collected following all aseptic precautions from patients and controls on the 28th day after administration of a second dose of Covishield vaccine and total antibodies to the severe acute respiratory syndrome coronavirus 2 spike (S) protein receptor binding domain was measured using Elecsys Anti-SARS-CoV-2 S kit from Roche.It was observed that no significant difference was there in antibody titre between cases and controls (6213 ± 4418 vs. 8331 ± 7979, P = 0.1022). It was also observed that no statistically significant difference in antibody titre in cases without prednisolone and those taking treatment with prednisolone was found (P = 0.7058). A similar observation was found in terms of methotrexate also (P = 0.457). No significant difference in antibody titres was there when compared with controls (for prednisolone, P = 0.169, for methotrexate, P = 0.078). We found that only the patients receiving mycophenolate mofetil showed a statistically significant decrease in antibody titre in comparison to healthy controls (P = 0.03). Our study showed no statistically significant difference in antibody titres between patients suffering from different AIRDs.Our study supplements the fact that patients with AIRDs in India can receive Covishield as the primary vaccine against COVID-19 without concerns regarding decreased immunogenicity or increased adverse effects.Copyright: © 2024 Journal of Family Medicine and Primary Care.